Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mastectomy, Segmental | 31 | 2022 | 953 | 3.810 |
Why?
|
Breast Neoplasms | 117 | 2024 | 21009 | 3.640 |
Why?
|
Mammaplasty | 22 | 2023 | 1239 | 2.970 |
Why?
|
Carcinoma, Ductal, Breast | 18 | 2024 | 1085 | 2.720 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 16 | 2024 | 926 | 2.460 |
Why?
|
Mastectomy | 38 | 2024 | 1822 | 2.400 |
Why?
|
Breast Implantation | 11 | 2022 | 223 | 2.400 |
Why?
|
Lymphedema | 19 | 2016 | 525 | 1.680 |
Why?
|
Neoplasm, Residual | 10 | 2024 | 1008 | 1.500 |
Why?
|
Breast Implants | 6 | 2022 | 411 | 1.280 |
Why?
|
Carcinoma, Lobular | 13 | 2020 | 481 | 1.260 |
Why?
|
Sentinel Lymph Node Biopsy | 16 | 2020 | 732 | 1.220 |
Why?
|
Nipples | 11 | 2024 | 229 | 1.180 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2024 | 9275 | 0.890 |
Why?
|
Lymph Node Excision | 10 | 2020 | 1273 | 0.830 |
Why?
|
Mammography | 14 | 2022 | 2429 | 0.710 |
Why?
|
Radio Frequency Identification Device | 1 | 2019 | 24 | 0.660 |
Why?
|
Surgery, Plastic | 3 | 2021 | 643 | 0.650 |
Why?
|
Mastectomy, Subcutaneous | 6 | 2024 | 56 | 0.600 |
Why?
|
Analgesics, Opioid | 4 | 2022 | 3801 | 0.600 |
Why?
|
Neoadjuvant Therapy | 6 | 2020 | 2823 | 0.580 |
Why?
|
Cathepsins | 1 | 2018 | 241 | 0.570 |
Why?
|
Mammary Glands, Human | 2 | 2014 | 203 | 0.510 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2020 | 464 | 0.500 |
Why?
|
Postoperative Complications | 17 | 2022 | 15647 | 0.450 |
Why?
|
Breast | 9 | 2020 | 1966 | 0.450 |
Why?
|
Female | 127 | 2024 | 392485 | 0.420 |
Why?
|
Lymph Nodes | 7 | 2020 | 3469 | 0.410 |
Why?
|
Retrospective Studies | 53 | 2023 | 80575 | 0.400 |
Why?
|
Axilla | 9 | 2020 | 624 | 0.400 |
Why?
|
Neoplasm Staging | 20 | 2020 | 11098 | 0.380 |
Why?
|
Reoperation | 6 | 2021 | 4302 | 0.370 |
Why?
|
Pain, Postoperative | 2 | 2019 | 1737 | 0.370 |
Why?
|
Middle Aged | 85 | 2024 | 220774 | 0.350 |
Why?
|
Length of Stay | 9 | 2022 | 6422 | 0.330 |
Why?
|
Tissue Expansion Devices | 2 | 2020 | 156 | 0.320 |
Why?
|
Adult | 82 | 2024 | 221122 | 0.320 |
Why?
|
Follow-Up Studies | 29 | 2024 | 39108 | 0.320 |
Why?
|
Biopsy | 6 | 2022 | 6768 | 0.320 |
Why?
|
Aged | 70 | 2024 | 169179 | 0.320 |
Why?
|
Arm | 5 | 2015 | 590 | 0.310 |
Why?
|
Humans | 134 | 2024 | 761326 | 0.310 |
Why?
|
Fiducial Markers | 2 | 2020 | 132 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2020 | 3512 | 0.300 |
Why?
|
Postoperative Period | 5 | 2022 | 1813 | 0.290 |
Why?
|
Nomograms | 2 | 2008 | 228 | 0.280 |
Why?
|
Radiotherapy, Conformal | 4 | 2014 | 548 | 0.270 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3531 | 0.260 |
Why?
|
Aged, 80 and over | 34 | 2020 | 58946 | 0.250 |
Why?
|
Surgical Flaps | 5 | 2020 | 1671 | 0.250 |
Why?
|
Quality Improvement | 1 | 2020 | 3800 | 0.240 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 318 | 0.240 |
Why?
|
Lymphatic Irradiation | 2 | 2015 | 115 | 0.230 |
Why?
|
Upper Extremity | 3 | 2013 | 657 | 0.210 |
Why?
|
Preoperative Care | 4 | 2020 | 2242 | 0.210 |
Why?
|
Lymphatic Metastasis | 10 | 2016 | 2914 | 0.200 |
Why?
|
Radiography, Interventional | 2 | 2020 | 1121 | 0.200 |
Why?
|
Prognosis | 17 | 2024 | 29588 | 0.200 |
Why?
|
Algorithms | 3 | 2021 | 14025 | 0.190 |
Why?
|
Medical Device Recalls | 1 | 2021 | 15 | 0.190 |
Why?
|
BRCA2 Protein | 3 | 2023 | 804 | 0.190 |
Why?
|
Silicone Gels | 1 | 2021 | 39 | 0.190 |
Why?
|
Prospective Studies | 26 | 2024 | 54405 | 0.190 |
Why?
|
Stomach | 2 | 2002 | 694 | 0.180 |
Why?
|
X-Ray Microtomography | 2 | 2013 | 455 | 0.180 |
Why?
|
Isoenzymes | 2 | 2003 | 1688 | 0.180 |
Why?
|
Patient Selection | 6 | 2020 | 4244 | 0.180 |
Why?
|
Peptide Hydrolases | 2 | 2021 | 621 | 0.170 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 476 | 0.170 |
Why?
|
Convalescence | 1 | 2020 | 105 | 0.170 |
Why?
|
Intraoperative Period | 2 | 2018 | 511 | 0.170 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 168 | 0.160 |
Why?
|
Treatment Outcome | 23 | 2022 | 64645 | 0.160 |
Why?
|
Urinary Bladder | 2 | 2002 | 1150 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3080 | 0.150 |
Why?
|
Carcinoma in Situ | 3 | 2015 | 791 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3200 | 0.150 |
Why?
|
Anesthesia, Conduction | 1 | 2001 | 262 | 0.150 |
Why?
|
Thyroid Diseases | 1 | 2001 | 386 | 0.150 |
Why?
|
Surface Properties | 1 | 2021 | 1160 | 0.150 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 587 | 0.150 |
Why?
|
Haploinsufficiency | 1 | 2020 | 337 | 0.150 |
Why?
|
Intraoperative Care | 2 | 2020 | 766 | 0.140 |
Why?
|
Risk Factors | 26 | 2021 | 74152 | 0.140 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2002 | 1170 | 0.140 |
Why?
|
Physical Exertion | 1 | 2020 | 667 | 0.140 |
Why?
|
Efficiency | 1 | 2020 | 476 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 1246 | 0.140 |
Why?
|
Radiodermatitis | 2 | 2014 | 58 | 0.140 |
Why?
|
Health Care Costs | 3 | 2019 | 3243 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 11735 | 0.130 |
Why?
|
Ultrasonography, Mammary | 1 | 2018 | 239 | 0.130 |
Why?
|
Histoplasmosis | 1 | 2016 | 63 | 0.130 |
Why?
|
Carcinoma, Papillary | 1 | 2001 | 784 | 0.130 |
Why?
|
Thyroidectomy | 1 | 2001 | 907 | 0.130 |
Why?
|
Magnetics | 1 | 2018 | 599 | 0.120 |
Why?
|
Combined Modality Therapy | 7 | 2019 | 8526 | 0.120 |
Why?
|
Neoplasm Invasiveness | 7 | 2024 | 3588 | 0.120 |
Why?
|
Needles | 1 | 2018 | 451 | 0.120 |
Why?
|
Pandemics | 5 | 2021 | 8635 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 801 | 0.120 |
Why?
|
Photons | 3 | 2014 | 589 | 0.120 |
Why?
|
Thyroid Nodule | 1 | 2002 | 764 | 0.120 |
Why?
|
Clinical Protocols | 1 | 2020 | 1440 | 0.120 |
Why?
|
Anesthesia, General | 1 | 2001 | 1174 | 0.120 |
Why?
|
Precancerous Conditions | 3 | 2017 | 978 | 0.120 |
Why?
|
Young Adult | 18 | 2021 | 59196 | 0.110 |
Why?
|
Costs and Cost Analysis | 3 | 2022 | 1668 | 0.110 |
Why?
|
Aftercare | 1 | 2020 | 913 | 0.110 |
Why?
|
Prosthesis Design | 1 | 2021 | 2115 | 0.110 |
Why?
|
Health Resources | 1 | 2020 | 935 | 0.110 |
Why?
|
Cellulitis | 1 | 2015 | 209 | 0.110 |
Why?
|
Perioperative Care | 2 | 2020 | 1034 | 0.110 |
Why?
|
Home Care Services | 1 | 2020 | 648 | 0.110 |
Why?
|
Health Behavior | 1 | 2004 | 2641 | 0.110 |
Why?
|
Risk Assessment | 8 | 2022 | 23981 | 0.100 |
Why?
|
Epigastric Arteries | 1 | 2013 | 92 | 0.100 |
Why?
|
Drosophila Proteins | 1 | 2001 | 1699 | 0.100 |
Why?
|
Body Mass Index | 6 | 2014 | 12949 | 0.100 |
Why?
|
Paget's Disease, Mammary | 1 | 2011 | 18 | 0.100 |
Why?
|
Survival Rate | 7 | 2024 | 12710 | 0.100 |
Why?
|
Thyroid Neoplasms | 2 | 2003 | 2332 | 0.100 |
Why?
|
Data Mining | 1 | 2016 | 551 | 0.100 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 249 | 0.090 |
Why?
|
Breast Diseases | 1 | 2014 | 442 | 0.090 |
Why?
|
Receptor, erbB-2 | 2 | 2018 | 2556 | 0.090 |
Why?
|
Laparoscopy | 1 | 2002 | 2035 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
Surgery, Computer-Assisted | 1 | 2018 | 1007 | 0.090 |
Why?
|
Ultrasonography, Interventional | 1 | 2018 | 1495 | 0.090 |
Why?
|
Anesthesiology | 1 | 2020 | 1117 | 0.090 |
Why?
|
Feasibility Studies | 5 | 2020 | 5247 | 0.080 |
Why?
|
Tumor Burden | 4 | 2019 | 1887 | 0.080 |
Why?
|
Specimen Handling | 1 | 2014 | 703 | 0.080 |
Why?
|
Radiographic Image Enhancement | 1 | 2014 | 876 | 0.080 |
Why?
|
Pectoralis Muscles | 2 | 2020 | 85 | 0.080 |
Why?
|
Nitriles | 1 | 2015 | 971 | 0.080 |
Why?
|
Continuity of Patient Care | 2 | 2015 | 1069 | 0.080 |
Why?
|
Triazoles | 1 | 2015 | 903 | 0.080 |
Why?
|
Radiotherapy Dosage | 4 | 2021 | 2898 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2020 | 1784 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 1112 | 0.080 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11070 | 0.080 |
Why?
|
Time Factors | 10 | 2020 | 39974 | 0.080 |
Why?
|
Seroma | 2 | 2022 | 75 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2016 | 12059 | 0.080 |
Why?
|
Lymphography | 1 | 2008 | 188 | 0.070 |
Why?
|
Splanchnic Circulation | 2 | 1999 | 119 | 0.070 |
Why?
|
Carcinoma, Ductal | 1 | 2008 | 97 | 0.070 |
Why?
|
Hyperplasia | 3 | 2017 | 1153 | 0.070 |
Why?
|
Pilot Projects | 5 | 2022 | 8632 | 0.070 |
Why?
|
Radiotherapy | 1 | 2014 | 1499 | 0.070 |
Why?
|
Postoperative Care | 2 | 2008 | 1471 | 0.070 |
Why?
|
Monitoring, Intraoperative | 1 | 2013 | 941 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 1519 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 6 | 2015 | 36430 | 0.070 |
Why?
|
Early Detection of Cancer | 5 | 2022 | 3200 | 0.070 |
Why?
|
Patient Readmission | 1 | 2020 | 3267 | 0.060 |
Why?
|
Body Weight | 2 | 2013 | 4614 | 0.060 |
Why?
|
Nerve Block | 1 | 2012 | 705 | 0.060 |
Why?
|
Fear | 1 | 2014 | 1476 | 0.060 |
Why?
|
Attitude to Health | 1 | 2014 | 2025 | 0.060 |
Why?
|
Point-of-Care Systems | 1 | 2014 | 1212 | 0.060 |
Why?
|
BRCA1 Protein | 2 | 2023 | 1155 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2859 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12450 | 0.060 |
Why?
|
Necrosis | 2 | 2022 | 1605 | 0.060 |
Why?
|
Brachytherapy | 1 | 2012 | 1223 | 0.060 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15262 | 0.060 |
Why?
|
Up-Regulation | 2 | 2003 | 4120 | 0.060 |
Why?
|
Peroxidases | 1 | 2003 | 134 | 0.060 |
Why?
|
Fat Necrosis | 2 | 2014 | 60 | 0.060 |
Why?
|
Age Factors | 6 | 2018 | 18401 | 0.050 |
Why?
|
Patient Care Team | 1 | 2015 | 2523 | 0.050 |
Why?
|
Hematoma | 2 | 2022 | 768 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 4063 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2008 | 968 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2020 | 6815 | 0.050 |
Why?
|
Medical Oncology | 1 | 2015 | 2321 | 0.050 |
Why?
|
Gastroepiploic Artery | 1 | 2002 | 2 | 0.050 |
Why?
|
Hypoalbuminemia | 1 | 2003 | 86 | 0.050 |
Why?
|
Cyclooxygenase 2 | 2 | 2003 | 597 | 0.050 |
Why?
|
Arteriovenous Anastomosis | 1 | 2002 | 14 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3041 | 0.050 |
Why?
|
Surgical Staplers | 1 | 2002 | 34 | 0.050 |
Why?
|
RNA, Antisense | 1 | 2003 | 136 | 0.050 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 2002 | 45 | 0.050 |
Why?
|
Calcitonin | 1 | 2003 | 329 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2005 | 956 | 0.050 |
Why?
|
Architectural Accessibility | 1 | 2021 | 24 | 0.050 |
Why?
|
Mutation | 5 | 2023 | 30044 | 0.050 |
Why?
|
Phorbol Esters | 1 | 2002 | 108 | 0.050 |
Why?
|
Androstadienes | 2 | 2015 | 348 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2012 | 5492 | 0.050 |
Why?
|
Quality of Life | 7 | 2022 | 13355 | 0.050 |
Why?
|
Surgical Stapling | 1 | 2002 | 98 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6473 | 0.050 |
Why?
|
Intensive Care Units | 3 | 2008 | 3744 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2016 | 20092 | 0.050 |
Why?
|
Area Under Curve | 1 | 2005 | 1633 | 0.050 |
Why?
|
Fatigue | 2 | 2022 | 1551 | 0.050 |
Why?
|
Substance Withdrawal Syndrome | 2 | 1996 | 625 | 0.050 |
Why?
|
Dopamine | 2 | 1999 | 1605 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 17872 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 78 | 0.050 |
Why?
|
Synovial Membrane | 1 | 2003 | 532 | 0.040 |
Why?
|
Incidence | 5 | 2019 | 21336 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7872 | 0.040 |
Why?
|
Dogs | 2 | 2002 | 3839 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4482 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 472 | 0.040 |
Why?
|
Gastric Mucosa | 2 | 2001 | 601 | 0.040 |
Why?
|
Carpal Tunnel Syndrome | 1 | 2003 | 303 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2001 | 225 | 0.040 |
Why?
|
Tissue Adhesives | 1 | 2001 | 173 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2006 | 3419 | 0.040 |
Why?
|
Ethanol | 2 | 1996 | 1324 | 0.040 |
Why?
|
Calcinosis | 1 | 2008 | 1469 | 0.040 |
Why?
|
Dobutamine | 1 | 1999 | 116 | 0.040 |
Why?
|
Protein Precursors | 1 | 2003 | 1134 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2016 | 4812 | 0.040 |
Why?
|
Organs at Risk | 1 | 2021 | 359 | 0.040 |
Why?
|
Genes, ras | 1 | 2001 | 653 | 0.040 |
Why?
|
Practice Guidelines as Topic | 3 | 2016 | 7389 | 0.040 |
Why?
|
Genetic Testing | 2 | 2009 | 3538 | 0.040 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4908 | 0.040 |
Why?
|
Patient Satisfaction | 3 | 2021 | 3460 | 0.040 |
Why?
|
Geographic Information Systems | 1 | 2020 | 281 | 0.040 |
Why?
|
Critical Care | 4 | 2008 | 2697 | 0.040 |
Why?
|
Materials Testing | 1 | 2001 | 864 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 2448 | 0.040 |
Why?
|
Telomerase | 1 | 2003 | 745 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2003 | 6128 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2020 | 310 | 0.030 |
Why?
|
Dopamine Agonists | 1 | 1999 | 352 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2002 | 1626 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 2008 | 14665 | 0.030 |
Why?
|
Radiography | 3 | 2013 | 6966 | 0.030 |
Why?
|
Workload | 1 | 2002 | 844 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 1999 | 539 | 0.030 |
Why?
|
Disease Progression | 1 | 2013 | 13500 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10075 | 0.030 |
Why?
|
Aneuploidy | 1 | 2020 | 551 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1571 | 0.030 |
Why?
|
Protons | 1 | 2021 | 1115 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2015 | 6231 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2001 | 3592 | 0.030 |
Why?
|
Fasting | 1 | 2022 | 1602 | 0.030 |
Why?
|
Nephritis | 1 | 2016 | 146 | 0.030 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 1995 | 26 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1637 | 0.030 |
Why?
|
Digestive System Neoplasms | 1 | 1995 | 81 | 0.030 |
Why?
|
Organ Specificity | 1 | 2020 | 1967 | 0.030 |
Why?
|
Perimenopause | 1 | 2016 | 142 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 12972 | 0.030 |
Why?
|
Device Removal | 1 | 2020 | 630 | 0.030 |
Why?
|
Alcoholism | 2 | 1996 | 1973 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4567 | 0.030 |
Why?
|
Coronary Artery Bypass | 1 | 2003 | 2189 | 0.030 |
Why?
|
Cohort Studies | 2 | 2014 | 41440 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1624 | 0.030 |
Why?
|
Arm Injuries | 1 | 2015 | 156 | 0.030 |
Why?
|
Blotting, Western | 1 | 2001 | 5034 | 0.030 |
Why?
|
Antineoplastic Protocols | 1 | 2014 | 48 | 0.030 |
Why?
|
Oxygen Consumption | 2 | 1999 | 1863 | 0.030 |
Why?
|
Coloring Agents | 1 | 2016 | 559 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 2016 | 376 | 0.030 |
Why?
|
Carbolines | 1 | 1995 | 294 | 0.030 |
Why?
|
Multiple Trauma | 1 | 1996 | 369 | 0.030 |
Why?
|
Heterozygote | 1 | 2020 | 2803 | 0.030 |
Why?
|
Models, Anatomic | 1 | 2016 | 683 | 0.030 |
Why?
|
Injections | 1 | 2015 | 830 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 1661 | 0.030 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 102 | 0.030 |
Why?
|
Skin Pigmentation | 1 | 2014 | 277 | 0.020 |
Why?
|
Premenopause | 1 | 2016 | 1039 | 0.020 |
Why?
|
Blood Pressure Determination | 1 | 2015 | 634 | 0.020 |
Why?
|
Mastectomy, Modified Radical | 1 | 2011 | 62 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2020 | 1901 | 0.020 |
Why?
|
Taxoids | 1 | 2015 | 666 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 312 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1858 | 0.020 |
Why?
|
Preoperative Period | 1 | 2013 | 551 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2016 | 856 | 0.020 |
Why?
|
General Surgery | 1 | 2002 | 1692 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 2020 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22158 | 0.020 |
Why?
|
Preventive Medicine | 1 | 2012 | 246 | 0.020 |
Why?
|
Logistic Models | 3 | 2015 | 13251 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2019 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 898 | 0.020 |
Why?
|
Mass Screening | 2 | 2021 | 5428 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2015 | 13333 | 0.020 |
Why?
|
Equipment Design | 1 | 2018 | 3510 | 0.020 |
Why?
|
Shock, Septic | 1 | 1997 | 768 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2015 | 1129 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2442 | 0.020 |
Why?
|
Photography | 1 | 2013 | 532 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2494 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2002 | 3666 | 0.020 |
Why?
|
Prosthesis-Related Infections | 1 | 2015 | 488 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2977 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2001 | 4509 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3303 | 0.020 |
Why?
|
Infrared Rays | 1 | 2010 | 247 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2504 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2003 | 7852 | 0.020 |
Why?
|
Sample Size | 1 | 2011 | 839 | 0.020 |
Why?
|
ROC Curve | 2 | 2008 | 3572 | 0.020 |
Why?
|
Tamoxifen | 1 | 2012 | 965 | 0.020 |
Why?
|
Operating Rooms | 1 | 2014 | 790 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
Postmenopause | 1 | 2016 | 2513 | 0.020 |
Why?
|
Cross Infection | 1 | 1996 | 1438 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2002 | 12787 | 0.020 |
Why?
|
Statistics, Nonparametric | 2 | 2006 | 2853 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2015 | 2208 | 0.020 |
Why?
|
Reference Standards | 1 | 2010 | 1004 | 0.020 |
Why?
|
Germany | 1 | 2008 | 875 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3878 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2015 | 2421 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2015 | 1525 | 0.020 |
Why?
|
Genes, BRCA2 | 1 | 2008 | 601 | 0.020 |
Why?
|
Sepsis | 1 | 1999 | 2587 | 0.020 |
Why?
|
Boston | 2 | 2008 | 9333 | 0.020 |
Why?
|
Esophageal Neoplasms | 1 | 1995 | 1647 | 0.020 |
Why?
|
Organ Size | 1 | 2010 | 2252 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8470 | 0.020 |
Why?
|
Genes, BRCA1 | 1 | 2008 | 764 | 0.020 |
Why?
|
Motor Activity | 1 | 2015 | 2710 | 0.020 |
Why?
|
Esthetics | 1 | 2006 | 330 | 0.010 |
Why?
|
Stroke Volume | 1 | 2018 | 5497 | 0.010 |
Why?
|
Electrons | 1 | 2006 | 265 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 1051 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2014 | 2319 | 0.010 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2163 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1336 | 0.010 |
Why?
|
Functional Laterality | 1 | 2010 | 2256 | 0.010 |
Why?
|
Osmotic Pressure | 1 | 2003 | 138 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 1996 | 2490 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 16966 | 0.010 |
Why?
|
Male | 11 | 2020 | 360621 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5883 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2002 | 18234 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9639 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2005 | 13635 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8527 | 0.010 |
Why?
|
Internship and Residency | 1 | 2002 | 5877 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1385 | 0.010 |
Why?
|
Self Report | 1 | 2013 | 3724 | 0.010 |
Why?
|
Risk | 1 | 2013 | 9605 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8223 | 0.010 |
Why?
|
Pain | 1 | 2016 | 5077 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7954 | 0.010 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2003 | 323 | 0.010 |
Why?
|
Tensile Strength | 1 | 2001 | 330 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10498 | 0.010 |
Why?
|
New York | 1 | 2002 | 874 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1265 | 0.010 |
Why?
|
Gastroplasty | 1 | 2001 | 157 | 0.010 |
Why?
|
Adolescent | 3 | 2008 | 88305 | 0.010 |
Why?
|
Primary Prevention | 1 | 2007 | 1186 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5970 | 0.010 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2002 | 495 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8837 | 0.010 |
Why?
|
Work Schedule Tolerance | 1 | 2002 | 551 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2001 | 983 | 0.010 |
Why?
|
Smoking | 1 | 2015 | 9051 | 0.010 |
Why?
|
Hospitals, University | 1 | 1999 | 564 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29858 | 0.010 |
Why?
|
Suture Techniques | 1 | 2001 | 771 | 0.010 |
Why?
|
Telomere | 1 | 2003 | 941 | 0.010 |
Why?
|
Chlormethiazole | 1 | 1995 | 1 | 0.010 |
Why?
|
Stress, Mechanical | 1 | 2001 | 1674 | 0.010 |
Why?
|
Flunitrazepam | 1 | 1995 | 20 | 0.010 |
Why?
|
Hospitalization | 1 | 1996 | 10715 | 0.010 |
Why?
|
Harmine | 1 | 1995 | 11 | 0.010 |
Why?
|
Alcohol Deterrents | 1 | 1996 | 49 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 1999 | 1370 | 0.010 |
Why?
|
Blood Gas Analysis | 1 | 1997 | 379 | 0.010 |
Why?
|
GABA Modulators | 1 | 1995 | 109 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4466 | 0.010 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1995 | 177 | 0.010 |
Why?
|
Clonidine | 1 | 1995 | 169 | 0.010 |
Why?
|
Dopamine Antagonists | 1 | 1995 | 288 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1999 | 2498 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 1999 | 2217 | 0.010 |
Why?
|
Microcirculation | 1 | 1999 | 1269 | 0.010 |
Why?
|
Trauma Severity Indices | 1 | 1996 | 478 | 0.010 |
Why?
|
Haloperidol | 1 | 1995 | 389 | 0.010 |
Why?
|
Animals | 2 | 2002 | 168388 | 0.010 |
Why?
|
Obesity | 1 | 2015 | 12934 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9468 | 0.010 |
Why?
|
Drug Combinations | 1 | 1995 | 2048 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 3889 | 0.000 |
Why?
|
Quality of Health Care | 1 | 2002 | 4330 | 0.000 |
Why?
|
Regression Analysis | 1 | 1997 | 6341 | 0.000 |
Why?
|
Apoptosis | 1 | 2003 | 9474 | 0.000 |
Why?
|
Hemodynamics | 1 | 1997 | 4167 | 0.000 |
Why?
|
Drug Therapy, Combination | 1 | 1996 | 6309 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 9605 | 0.000 |
Why?
|
Respiration, Artificial | 1 | 1996 | 2625 | 0.000 |
Why?
|